ZA201706391B - Crystalline forms of 1¿((2r,4r)¿2¿(1h¿benzo[d]imidazol¿2¿yl)¿1¿methylpiperidin¿4¿yl)¿3¿(4¿cyanophenyl)urea maleate - Google Patents

Crystalline forms of 1¿((2r,4r)¿2¿(1h¿benzo[d]imidazol¿2¿yl)¿1¿methylpiperidin¿4¿yl)¿3¿(4¿cyanophenyl)urea maleate

Info

Publication number
ZA201706391B
ZA201706391B ZA2017/06391A ZA201706391A ZA201706391B ZA 201706391 B ZA201706391 B ZA 201706391B ZA 2017/06391 A ZA2017/06391 A ZA 2017/06391A ZA 201706391 A ZA201706391 A ZA 201706391A ZA 201706391 B ZA201706391 B ZA 201706391B
Authority
ZA
South Africa
Prior art keywords
methylpiperidin
cyanophenyl
imidazol
benzo
crystalline forms
Prior art date
Application number
ZA2017/06391A
Other languages
English (en)
Inventor
Eric Christian Hansen
Christopher Scott Seadeek
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201706391(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ZA201706391B publication Critical patent/ZA201706391B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2017/06391A 2015-04-24 2017-09-21 Crystalline forms of 1¿((2r,4r)¿2¿(1h¿benzo[d]imidazol¿2¿yl)¿1¿methylpiperidin¿4¿yl)¿3¿(4¿cyanophenyl)urea maleate ZA201706391B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562152108P 2015-04-24 2015-04-24
PCT/IB2016/052107 WO2016170451A1 (en) 2015-04-24 2016-04-13 Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate

Publications (1)

Publication Number Publication Date
ZA201706391B true ZA201706391B (en) 2020-12-23

Family

ID=55806563

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/06391A ZA201706391B (en) 2015-04-24 2017-09-21 Crystalline forms of 1¿((2r,4r)¿2¿(1h¿benzo[d]imidazol¿2¿yl)¿1¿methylpiperidin¿4¿yl)¿3¿(4¿cyanophenyl)urea maleate

Country Status (24)

Country Link
US (4) US10414748B2 (cg-RX-API-DMAC10.html)
EP (2) EP3286176B1 (cg-RX-API-DMAC10.html)
JP (1) JP6345728B2 (cg-RX-API-DMAC10.html)
KR (2) KR20190038677A (cg-RX-API-DMAC10.html)
CN (1) CN107531667A (cg-RX-API-DMAC10.html)
AR (1) AR104391A1 (cg-RX-API-DMAC10.html)
AU (1) AU2016251940C1 (cg-RX-API-DMAC10.html)
BR (1) BR112017021075B1 (cg-RX-API-DMAC10.html)
CA (2) CA2983387C (cg-RX-API-DMAC10.html)
CY (2) CY1124056T1 (cg-RX-API-DMAC10.html)
DK (2) DK3286176T3 (cg-RX-API-DMAC10.html)
ES (2) ES2774053T3 (cg-RX-API-DMAC10.html)
HK (1) HK1243416A1 (cg-RX-API-DMAC10.html)
HU (2) HUE059506T2 (cg-RX-API-DMAC10.html)
IL (1) IL255224B (cg-RX-API-DMAC10.html)
MX (1) MX375384B (cg-RX-API-DMAC10.html)
PL (2) PL3286176T3 (cg-RX-API-DMAC10.html)
PT (2) PT3286176T (cg-RX-API-DMAC10.html)
RU (1) RU2717564C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201707863QA (cg-RX-API-DMAC10.html)
SI (2) SI3666768T1 (cg-RX-API-DMAC10.html)
TW (1) TWI646093B (cg-RX-API-DMAC10.html)
WO (1) WO2016170451A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201706391B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3286176B1 (en) 2015-04-24 2020-01-15 Pfizer Inc Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
US12668581B2 (en) * 2020-01-28 2026-06-30 Assia Chemical Industries Ltd. Processes for the preparation of Glasdegib and salt thereof and solid state forms of Glasdegib maleate and process for preparation thereof
WO2021191278A1 (en) 2020-03-26 2021-09-30 Lek Pharmaceuticals D.D. Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy
WO2023017541A1 (en) * 2021-08-12 2023-02-16 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methyl piperidin-4-yl)-3-(4-cyanophenyl)urea maleate
CN114668849B (zh) * 2021-12-31 2024-01-23 中国人民解放军军事科学院军事医学研究院 Shh通路调控生物节律及其相关应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US8253800B2 (en) 2006-06-28 2012-08-28 Nikon Corporation Tracking device, automatic focusing device, and camera
CA2690953C (en) * 2007-06-29 2012-10-02 Pfizer Inc. Benzimidazole derivatives
EP3286176B1 (en) 2015-04-24 2020-01-15 Pfizer Inc Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate

Also Published As

Publication number Publication date
CA2983387C (en) 2022-08-16
CY1124056T1 (el) 2022-03-24
DK3666768T3 (da) 2022-06-27
HK1243416A1 (zh) 2018-07-13
AR104391A1 (es) 2017-07-19
US20220024894A1 (en) 2022-01-27
BR112017021075A2 (pt) 2018-07-03
RU2017137269A3 (cg-RX-API-DMAC10.html) 2019-09-13
US11891373B2 (en) 2024-02-06
AU2016251940A1 (en) 2017-10-12
CA2983387A1 (en) 2016-10-27
JP2016204373A (ja) 2016-12-08
KR102078444B1 (ko) 2020-02-17
SI3666768T1 (sl) 2022-09-30
PT3286176T (pt) 2020-02-24
HUE059506T2 (hu) 2022-11-28
SG11201707863QA (en) 2017-11-29
AU2016251940B2 (en) 2018-08-30
MX375384B (es) 2025-03-06
ES2923593T3 (es) 2022-09-28
EP3666768B1 (en) 2022-06-15
US20190382368A1 (en) 2019-12-19
US10414748B2 (en) 2019-09-17
IL255224B (en) 2021-01-31
IL255224A0 (en) 2017-12-31
HUE048664T2 (hu) 2020-07-28
SI3286176T1 (sl) 2020-04-30
KR20170129245A (ko) 2017-11-24
DK3286176T3 (da) 2020-03-02
US20180086731A1 (en) 2018-03-29
CA2927736A1 (en) 2016-10-24
JP6345728B2 (ja) 2018-06-20
TWI646093B (zh) 2019-01-01
RU2717564C2 (ru) 2020-03-24
CN107531667A (zh) 2018-01-02
US11168066B2 (en) 2021-11-09
EP3286176B1 (en) 2020-01-15
MX2017013645A (es) 2018-03-08
RU2017137269A (ru) 2019-05-24
ES2774053T3 (es) 2020-07-16
PL3666768T3 (pl) 2022-09-19
AU2016251940C1 (en) 2019-04-11
PL3286176T3 (pl) 2020-11-30
US11891372B2 (en) 2024-02-06
KR20190038677A (ko) 2019-04-08
BR112017021075B1 (pt) 2021-08-03
NZ735719A (en) 2020-11-27
WO2016170451A1 (en) 2016-10-27
US20220024893A1 (en) 2022-01-27
TW201702238A (zh) 2017-01-16
CY1125333T1 (el) 2025-03-28
PT3666768T (pt) 2022-07-22
EP3666768A1 (en) 2020-06-17
EP3286176A1 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
IL272056A (en) Heterocyclic compounds as adenosine antagonists
PL3359542T3 (pl) Związki i pochodne spiro[3h-indolo-3,2’-pirolidyno]-2(1h)-onowe jako inhibitory mdm2-p53
ZA201802797B (en) 2-(het)aryl-substituted condensed bicyclic heterocyclic derivatives as pest control agents
IL284767A (en) Heterocyclic compounds as adenosine antagonists
IL250280A0 (en) New and novel spiro[3h-indole-3, 2'-pyrrolidine]-2(1h)-one compounds as mdm2-p53 inhibitors
SG11201708707UA (en) Heterocyclic amides as kinase inhibitors
IL255750A (en) Heterocyclic compounds as kinase inhibitors
IL253731A0 (en) Crystal forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1, 2,4-triazole-3-carboxamide
SG11202001337XA (en) Bezimidazole derivatives as adenosine receptor antagonists
IL293103B2 (en) History of pyridopyrimidinones as AHR antagonists
IL255224B (en) Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
SG11202001340VA (en) Quinoxaline derivatives as adenosine receptor antagonists
IL284762A (en) Heterocyclic compounds as adenosine antagonists
IL255937B (en) Heterocyclic compounds 3,3-difluoropiperidine carbamate as nr2b nmda receptor antagonists
SI3625221T1 (sl) Derivati 3-metil-pirolidin-2,5-diona uporabni kot antagonisti CGRP receptorja
IL248918A0 (en) Crystal structure of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
HK40029095A (en) Heterocyclic compounds as adenosine antagonists
HK40064784A (en) Heterocyclic compounds as adenosine antagonists
PL3621966T3 (pl) Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK